THE WHAT? Galderma reported strong first-quarter 2026 results, with net sales reaching US$1.47 billion and significant year-on-year growth.

THE DETAILS The dermatology-focused company delivered 25.5% growth at constant currency, driven primarily by volume alongside positive pricing and mix effects. Growth was broad-based across all categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%), supported by strong performance from brands like Cetaphil, Alastin and Restylane, as well as the continued rollout of Nemluvio. The company also highlighted ongoing innovation, clinical data advancements and geographic expansion, while strengthening its financial position through share buybacks, a €500 million Eurobond issuance and full exit of its private equity backers.

THE WHY? The results reflect the success of Galderma’s integrated dermatology strategy, combining innovation, portfolio expansion and global execution to outperform the market and drive sustained growth.

Source: Galderma